Consideration of existing compounds always simplifies and shortens the long and difficult
process of discovering new drugs specifically for diseases of developing countries, an …

Praziquantel is the drug of first choice for the treatment of the human schistosomiasis. It is
administered orally, requiring high doses to overcome adverse biopharmaceutical …

Schistosomiasis is a devastating endemic water born tropical disease caused by a parasitic
flat worm of the genus Schistosoma. It is usually associated with poverty, causing significant …

Background Schistosomiasis is responsible for a considerable global disease burden. This
work aimed to improve the therapeutic outcome of the only available antischistosomal drug …

Praziquantel (PZQ) is a pyrazinoisoquinoline anthelmintic that was discovered in 1972 by
Bayer Germany. Currently, due to its efficacy, PZQ is the drug of choice against all species of …

Praziquantel (PZQ) is an anthelmintic of choice in the treatment of schistosomiasis. Solvent
evaporation technique produced three different Solid Dispersions (SD)(drug: polymer, w/w) …

Schistosomiasis is a widely distributed parasitic disease and one of the most important
neglected tropical diseases globally, for which Praziquantel®(PZQ) is the only available …

Currently, schistosomiasis mansoni is treated clinically with praziquantel (PZQ).
Nevertheless, cases of tolerance and resistance to this drug have been reported, creating …

The control of schistosomiasis depends exclusively on praziquantel (PZQ) monotherapy with
treatment failure due to minor activity against the juvenile stage, re-infection and emerging …

Introduction: Among all the anti-schistosomal drugs, praziquantel has been the most widely
used. However, some major challenges have been faced using the drug in the treatment of …